Zacks Research Comments on Novavax FY2027 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Equities research analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Novavax in a report issued on Thursday, March 20th. Zacks Research analyst S. Ganoria forecasts that the biopharmaceutical company will post earnings per share of $0.54 for the year. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to analysts’ expectations of $85.48 million. During the same period in the prior year, the business posted ($1.44) EPS.

A number of other research analysts have also recently issued reports on NVAX. HC Wainwright reiterated a “buy” rating and set a $19.00 price objective on shares of Novavax in a research note on Tuesday, December 10th. TD Cowen raised shares of Novavax to a “hold” rating in a research report on Thursday, February 27th. Finally, BTIG Research started coverage on shares of Novavax in a report on Friday, February 28th. They issued a “buy” rating and a $19.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Novavax currently has a consensus rating of “Hold” and a consensus target price of $18.00.

Novavax Stock Performance

Shares of NVAX opened at $7.69 on Monday. The firm’s 50-day simple moving average is $8.23 and its two-hundred day simple moving average is $9.46. Novavax has a fifty-two week low of $3.81 and a fifty-two week high of $23.86. The stock has a market cap of $1.24 billion, a PE ratio of -3.40, a price-to-earnings-growth ratio of 2.85 and a beta of 2.92.

Hedge Funds Weigh In On Novavax

A number of hedge funds have recently modified their holdings of NVAX. E Fund Management Co. Ltd. lifted its holdings in shares of Novavax by 5.1% in the fourth quarter. E Fund Management Co. Ltd. now owns 25,340 shares of the biopharmaceutical company’s stock worth $204,000 after buying an additional 1,219 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Novavax by 0.4% in the 4th quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company’s stock worth $3,509,000 after buying an additional 1,664 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Novavax by 12.0% in the 3rd quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 2,072 shares during the last quarter. Federated Hermes Inc. raised its position in shares of Novavax by 4.4% during the 4th quarter. Federated Hermes Inc. now owns 50,506 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 2,124 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its holdings in shares of Novavax by 16.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 16,126 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 2,287 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director James F. Young sold 5,400 shares of Novavax stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the transaction, the director now directly owns 51,760 shares of the company’s stock, valued at $414,080. The trade was a 9.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.00% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.